FDA
Approves Flexible Administration Schedule For
Lantus
Aventis announced that its basal insulin, Lantus®,
has been approved by the U.S. Food and Drug Administration
for flexible administration at any time of day.
Lantus
is the first and only basal insulin analog that
provides 24-hour glucose lowering activity with
just one injection. This new approval in the dosing
schedule for Lantus from once daily at bedtime
to flexible daily dosing means patients using
Lantus may have more options in managing their
diabetes.
The
long lasting basal insulin should be administered
once daily at any time, but at the same time each
day.
Basal insulin therapy can effectively help patients
with diabetes achieve tight blood sugar control,
defined by the American Diabetes Association (ADA)
as an A1C<7.0 percent and by the International
Diabetes Federation (IDF) as an A1C<6.5 percent;
however, less than half of the more than 11 million
Americans diagnosed with diabetes are meeting
these blood sugar goals. Worldwide, less than
20 percent of the people with diabetes have good
metabolic control.
Lantus
demonstrates a slow, prolonged absorption and
a relatively constant concentration/time profile
over 24 hours. It is unique in that it has no
pronounced peak. Lantus also has a consistent
delivery of insulin and similar absorption and
consistency of action regardless of injection
site. Source: Aventis
For full prescribing information, please visit:
http://www.lantus.com.
================================
Special Feature:
The Results of the Diabetes In Control 10,000
Step Study:
30 MILLON STEPS &15,000 Miles LATER!
Find out how to start your own STEP Program
in your office.
.
